Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.

ABSTRACT: The goals of treatment for metastatic breast cancer (MBC) are to prolong overall survival (OS) while maximizing quality of life, palliating symptoms, and delaying tumor progression. For many years, anthracyclines and taxanes have been the mainstay of treatment for MBC, but these agents are now commonly administered earlier in the course of the disease. A recent meta-analysis revealed adverse effects on OS and overall response rates in patients with MBC receiving first-line anthracycline-based chemotherapy following relapse on adjuvant chemotherapy. Noncrossresistant cytotoxic agents and combinations that combine high clinical activity and acceptable tolerability while being convenient for patients are therefore needed for the first-line treatment of MBC patients. Capecitabine has substanti

SUBMITTER: O'Shaughnessy JA 

PROVIDER: S-EPMC3336834 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature